As I have mentioned a few times COVID-19 has meant that we have had to change the pathway priorities we are working on so the clinical plan presented last November is somewhat out of date. The positive is overall progress is unaffected, but some pathways are further along than we planned and some a bit behind. This one of the huge advantages of having multiple pathways to progress is that we can juggle them to match what the real world throws at us.
One thing I should mention in regards MRD is treatment is initiated at a time point functionally equivalent to where Bisantrene was used in the historical trials (i.e. 2nd line). All the modern issues resulting from all the new treatments with r/r AML are avoided and we have a patient population similar to what was seen in the 1980s. In someways MRD is a less risky option than r/r AML because the historical data is more relevant.
-
- There are more pages in this discussion • 306 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
